About
Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture arm of Takeda Pharmaceuticals Limited.
Tags
Total Employees
91
Current headcount
Performance
Company Timeline
No timeline data for this period
Score Breakdown
62Traction
59Team
30Visibility
38Profile
70Community
0Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Emendo Biotherapeutics do?
Emendo is a genome editing company developing genetic medicines and cell therapies for severe diseases. Emendo's cutting-edge technology is based on its proprietary protein engineering and selection platforms, designed to generate ultra-specific and highly active CRISPR OMNI nucleases, carefully optimized per target sequence for generating safe and effective genetic solution. Emendo was established in 2015 with investments by OrbiMed Advisors LLP And Takeda Ventures, Inc. the corporate venture a…
How much funding has Emendo Biotherapeutics raised?
Emendo Biotherapeutics has raised a total of $61M in funding. The most recent round on record is Series B.
When was Emendo Biotherapeutics founded?
Emendo Biotherapeutics was founded in 2015.
What industry does Emendo Biotherapeutics operate in?
Emendo Biotherapeutics operates in Healthcare, Genome Editing, CRISPR.
How many employees does Emendo Biotherapeutics have?
Emendo Biotherapeutics has approximately 91 people on record.
What is Emendo Biotherapeutics's current status?
Emendo Biotherapeutics's current operating status is: Acquired.